STUDY PROTOCOL

LUNCH—Lung Ultrasound for early detection of silent and apparent aspiration in infants and young children with cerebral palsy and other developmental disabilities: study protocol of a randomized controlled trial

S Fiori1,2*, RT Scaramuzzo3, E Moretti1, C Amador1, T Controzzi3, A Martinelli1, L Filippi3, A Guzzetta1,2 and L Gargagni4

Abstract

Background: Children with neurological impairment may have dysphagia and/or gastro-esophageal reflux disease (GERD), which predispose to complications affecting the airways, increasing risk for aspiration-induced acute and chronic lung disease, or secondarily malnutrition, further neurodevelopmental disturbances, stressful interactions with their caregivers and chronic pain. Only multidisciplinary clinical feeding evaluation and empirical trials are applied to provide support to the management of feeding difficulties related to dysphagia or GERD, but no standardized feeding or behavioral measure exists at any age to assess aspiration risk and support the indication to perform a videofluoroscopic swallowing study (VFSS) or a fibre-optic endoscopic examination of swallowing (FEES), in particular in newborns and infants with neurological impairments. Lung ultrasound (LUS) has been proposed as a non-invasive, radiation-free tool for the diagnosis of pulmonary conditions in infants, with high sensitivity and specificity.

Methods: A RCT will be conducted in infants aged between 0 and 6 years having, or being at risk for, cerebral palsy, or other neurodevelopmental disease that determines abnormal muscular tone or motor developmental delay assessed by a quantitative scale for infants or if there is the suspicion of GERD or dysphagia based on clinical symptoms. Infants will be allocated in one of 2 groups: 1) LUS-monitored management (LUS-m); 2) Standard care management (SC-m) and after baseline assessment (T0), both groups will undergo an experimental 6-months follow-up. In the first 3 months, infants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 LUS-monitored meal evaluations. Primary and secondary endpoint measures will be collected at 3 and 6 months.

Discussion: This paper describes the study protocol consisting of a RCT with two main objectives: (1) to evaluate the benefits of the use of LUS for monitoring silent and apparent aspiration in the management of dysphagia and its impact on pulmonary illness and growth and (2) to investigate the impact of the LUS management on blood sample and bone metabolism, pain and interaction with caregivers.

*Correspondence: simona.fiori@fsm.unipi.it

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Children with neurological impairment commonly experience abnormal ingestion functions (WHO, http://apps.who.int/classifications/icfbrowser/), including impairment in oral-motor function, rumination, abnormal swallowing, regurgitation and vomiting, defined as dysphagia and/or gastro-esophageal reflux disease (GERD), delayed gastric emptying and constipation [1, 2]. The number of these children is estimated not to decline in the next years, and their life expectancy to increase [3]. The neurological impairment may arise from a variety of disorders, including cerebral palsy or rare paediatric diseases such as genetic, metabolic, muscular and movement disorders. Primary or secondary muscle tone abnormalities in these disorders contribute to dysphagia and/or GERD, which predispose to complications affecting the airways, increasing risk for insidious development of aspiration-induced acute and chronic lung disease, or secondary malnutrition, further neurodevelopmental disturbances, and stressful interactions with their caregivers [4–6]. Moreover, infants with GERD likely experience chronic pain: inability to settle, grimacing, tense body, hypo- or hyper-reactions to acute pain, and deregulated sleep are possible indicators, even if no current definitions exist that are wholly applicable to infancy [7].

In such patients, a failure to thrive is the sum of nutritional and non-nutritional factors (mainly frequent respiratory infections and chronic pain, as well as use of antiepileptic medication). Malnutrition per se is due to feeding difficulties (with consequent insufficient dietary intake or excessive nutrient losses) and altered energy metabolism, and is associated to micronutrients deficiencies and osteopenia [8]. In the last couple of decades, the nutritional needs of children with neurological impairment have become a major matter of interest so that, in 2017, the European Society of Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published a consensus statement (ESPGHAN guidelines) on the diagnosis and management of gastrointestinal and nutritional complications in children with neurological disability [9]. Both diagnosis of GERD and accurate monitoring of growth and nutritional status are among the “top ten-tips” in managing nutritional issues and gastrointestinal function in neurologically impaired children [10].

Oral fluid, food or refluxed gastric contents can be aspirated into the lungs, apparently, by choking or coughing, or silently. In order to directly or indirectly diagnose aspiration in dysphagia and GERD, video-fluoroscopic swallowing study (VFSS) and fiber-optic endoscopic examination of swallowing (FEES) are options, however they focus on a single study, thus clinical diagnosis is seldom made despite a normal result and, due to radiation exposure, invasiveness and costs, they are poorly reproducible in the same patient [11–13]. Furthermore, rheological and material property parameters among the barium-impregnated liquids and the thickened and unthicken infant formula are different, thus biasing the interpretation of the radiological results and consequent clinical recommendations [13, 14]. Finally, only clinical feeding evaluation and empirical trials are applied to provide support to the management of feeding difficulties related to dysphagia or GERD, and no standardized feeding or behavioral measure exists at any age to assess aspiration risk and support the indication to perform VFSS or FEES.

The picture is further complicated at young ages, as recently the concept of ‘early diagnosis’ has emerged for cerebral palsy and a variety of neurological disorders [15]. Indeed, most studies focusing on dysphagia and GERD in neurologically impaired children refer to ages older than 1 year. In the few studies investigating dysphagia in infants younger than 1 year by using VFSS, aspiration was present in 50% of infants with suspected dysphagia and up to 90% of them had silent aspiration [16]. This indicates that many infants who are not clinically suspected of having dysphagia or GERD may have silent aspiration, therefore a monitoring would be recommended in infants with higher aspiration risk, starting early from the first days of life. This would lead to earlier diagnosis, clinical management ad tailored habilitation and nutritional strategies to improve outcome and limit short-term and long-term complications [17].

Lung ultrasound (LUS) has been proposed and gained consensus as a non-invasive, radiation-free tool for the diagnosis of acute and chronic pulmonary conditions in both infants and adults, with high sensitivity and specificity in several conditions [18–22] LUS is an easy technique that may be performed during routine physical examination, with a point-of-care approach. Previous studies demonstrated that LUS is able to detect small lung consolidations with very high accuracy [22], and can be effectively used to follow-up the dynamic changes of these lesions. LUS is a patient-friendly tool, especially in young children, who are particularly susceptible to radiation exposure, which can impact later in their life with an increase risk of cancer [23].

**Trial registration:** Trial registration date 02/05/2020; ClinicalTrials.gov Identifier: NCT04253951.

**Keywords:** Dysphagia, Neurological impairment, Infant, Lung ultrasound (LUS), Aspiration, GERD
The trial is conceived as a double-blinded randomized parallel-designed controlled trial (Consort checklist, [24]), comparing LUS-monitored management and standard care.

We hypothesize infants receiving LUS-monitored management having lower rate of pulmonary illness and better growth curves, and also reduce the need for invasive diagnostic (VFSS/FEES) over time. We also hypothesize infants receiving LUS-monitored management will have better biochemical and bone metabolism results, lower pain indices and less stressful interaction with caregivers.

Methods
The presented protocol consists of a RCT, which compares LUS-monitored management of dysphagia-related aspiration versus standard care management in infants with neurological impairment. Study timeline is scheduled in Fig. 1.

The main aim of the presented trial is to explore the effectiveness of the use of LUS for monitoring pulmonary abnormalities related to aspiration during feeding in neurologically impaired infants, by comparing integrated LUS-monitored management of dysphagia to standard care in terms of medical/neurological/behavioral status, chronic pain/discomfort and stress for caregivers.

Specific hypotheses to be tested are:

1) Infants receiving LUS-monitored management will have lower rate of pulmonary illness and better growth curves, corresponding to less after-meal LUS abnormalities over time, compared to infants receiving standard care. They will also reduce the need for invasive diagnostic (VFSS/FEES) over time.

2) Infants receiving LUS-monitored management will have better results at blood sample and bone metabolism, lower pain indices and less stressful interaction with caregivers.

We also hypothesized that diagnostic benefits of LUS-monitored management will contribute to better neurological outcome.

Further aims also include the comparison between LUS andVFSS/FEES in the detection of feeding-related silent or apparent aspiration and to estimate aspiration entity by cut-off values for the diagnosis of clinically significant silent or overt aspiration, responsiveness of LUS monitoring to medical, postural or food consistencies adaptation, and their relationship with standardized clinical feeding evaluation and medical/behavioral/neurological measures. Moreover, we will explore the impact of brain abnormalities detected by brain MRI on LUS findings severity.

We will finally establish risk categories for unsafe swallowing disorders and potential clinical recommendations for early management.

Participants
A minimum sample size of 126 subjects was determined (63 each group). Newborn and infants will be recruited by the child neurologist and the speech and language pathologist (SLP) from the Infant Neurology Section of academic hospital IRCCS Stella Maris Foundation in Pisa, Italy.

Subjects will be included in the study if: i) they have, or they are at risk for, cerebral palsy [15] or have abnormal muscular tone at any age between 0–6 years of life due disorders other than cerebral palsy; or ii) motor developmental delay assessed by a quantitative scale for infants and young children development (< 5 sd according to age); or iii) in absence of the previous clinical indices, if there is the suspicion of GERD or dysphagia based on clinical symptoms; iv) a brain MRI acquisition done before or programmed prior the end of the study period as part of their diagnostic procedure. Subjects will be excluded in presence of primary chronic lung diseases.

Procedure
The medical staff of the recruiting center will refer eligible infants to researchers. Researchers will provide parents/guardians detailed information about the study procedures and seek informed consent. Assessments and procedures included in the study will be provided at IRCCS Stella Maris Foundation and Azienda Ospedaliero-Universitaria Pisana (AOUP), Pisa.

Also, the portable LUS machines that is used will allow the opportunity for home LUS evaluation to improve compliance of the patients to the experimental follow-up period.

Study design
The trial is conceived as a double-blinded randomized parallel-designed controlled trial (Consort checklist, [24]), with block randomization (blocks of size 4), in one of 2 groups: 1) LUS-monitored (LUS-m) management; 2) Standard care management (SC-m).

Demographic data and motor, medical, neurodevelopmental and other associated measures, including brain MRI data, will be collected after participants’ parents/guardians have provided informed consent.

After baseline assessment (T0), both groups will undergo an experimental 6-months follow-up. When possible, in order to increase patients’ compliance to the protocol, experimental evaluation will be included in the clinical follow-up of the subject. In the first 3 months, participants will be evaluated a minimum
of 1 time per month, in-hospital, for a total of 3 LUS-monitored meal evaluations, plus baseline (T0). Three months (T1) will be the primary endpoint. A further 6-months LUS-monitored meal and clinical assessment (T2) will be delivered. Primary and secondary outcome measures will be collected at T1 (primary outcome measures endpoint) and T2 (stability of outcome) (Fig. 1).

Study characteristics are detailed in Table 1.

| STUDY PERIOD | Enrolment | Allocation | Post-allocation |
|--------------|-----------|------------|----------------|
| TIMEPOINT**  | T0        | T1 (3 months) | T2 (6 months) |
| ENROLMENT:   |           |            |                |
| Eligibility screen | X        |            |                |
| Informed consent    | X        |            |                |
| Allocation      | X        |            |                |
| INTERVENTIONS:  |           |            |                |
| LUS-m          |           |            |                |
| SC-m           |           |            |                |
| ASSESSMENTS:   |           |            |                |
| LUS            | X         | X          | X              |
| HINE           | X         | X          | X              |
| AIMS           | X         | X          | X              |
| GMFCS E&R      | X         |            | X              |
| Rate of pulmonary illness | X        |            | X              |
| Performance at growth curves | X       | X          | X              |
| NCCPC          | X         | X          | X              |
| PSI            | X         |            | X              |
| laboratory exams* | X      | X          |                |
| QUS            | X         |            | X              |

LUS: lung ultrasound; LUS-m: LUS monitored; SC-m: standard care management; HINE: Hammersmith Infant Neurological Examination; AIMS: Alberta Infant Motor Scale; NCCPC: Non-communicating Children's Pain Checklist; PSI: parenting stress index; QUS: quantitative ultrasound; *blood cells count, reticulocytes count, ferritin, total serum protein and electrophoresis, prealbumin, transferrin, TSH, FT3, FT4, sodium, potassium, calcium, phosphorus, folates, vitamin B12, 25-OH-vitamin D, C-reactive protein, erythrocyte sedimentation rate

Fig. 1 Schedule of study enrolment, interventions, and assessments
Sample size determination
The required sample size was calculated according to one of the primary outcome measures, which is the difference in LUS scores at T1 between assignment groups, based on preliminary results (alpha = 0.05, power (1 - ß err prob) = 80%, effect size f = 1.6) (unpublished data).

Estimating a conservative attrition rate of 15%, our sample size will include 150 participants over 30 months.

Randomization/blinding
After enrolment, participants will be randomly assigned to LUS-monitored or standard care group by the use of block-generator software. Both the clinicians who will perform and score LUS, and the patients’ family will be blinded to randomization.

The child neurologist and the SLP will be informed of the result of LUS only in the LUS-m group and will include that result to impact on feeding care (postural-hygiene care adaptation, thickening fluids or drugs available for GERD). LUS results in the SC-m group will be available only at the time of data analyses.

Adverse events
Any adverse event or unintended effect associated with the intervention will be reported and reviewed by researchers. In case of detection of LUS pulmonary abnormalities that will be considered a medical emergency which compromises a participant’s safety, unblinding will be permissible. The child neurologist will be informed of the unlikely result and will inform the family for appropriate therapy.

LUS procedure/Equipment
The intervention is a LUS-monitored (before and after) feeding trial (the “after” evaluation will be within 15 min the end of the feeding procedure). A further LUS evaluation will be performed at a distance of 3 h, before the next meal to check for resolution of eventual after-meal

---

Table 1  Summary of trial characteristics

| Recruiting | Information |
|------------|-------------|
| Primary registry and trial identifying number | ClinicalTrials.gov Identifier: NCT04253951 |
| Date of registration in primary registry | 05 February, 2020 |
| Source(s) of monetary or material support | Italian Ministry of Health |
| Primary sponsor | Italian Ministry of Health |
| Contact for public queries | SF, MD, PHD simona.fiori@fsm.unipi.it |
| Contact for scientific queries | SF, MD, PHD simona.fiori@fsm.unipi.it |
| IRCCS Fondazione Stella Maris, Pisa, Italy |
| Public title | LUNCH—Lung Ultrasound for early detection of silent and apparent aspiration in infants and young children with cerebral palsy and other developmental disabilities: study protocol of a randomized controlled trial |
| Scientific title | LUNCH—Lung Ultrasound for early detection of silent and apparent aspiration in infants and young children with cerebral palsy and other developmental disabilities: study protocol of a randomized controlled trial |
| Countries of recruitment | Italy |
| Health condition(s) or problem(s) studied | Aspiration in pediatric cerebral palsy and developmental disabilities |
| Health condition(s) or problem(s) studied | Active comparator: Lung ultrasound monitored management |
| Health condition(s) or problem(s) studied | Standard care |
| Key inclusion and exclusion criteria | Ages eligible for study: 0–6 years |
| Sexes eligible for study: both |
| Accepts healthy volunteers: no |
| Inclusion criteria: infant and children < 6 years; with, or at risk for, cerebral palsy or abnormal muscular tone due disorders other than cerebral palsy; suspicion of GERD or dysphagia based on clinical symptoms |
| Exclusion criteria: primary chronic lung diseases |
| Study type | Intervventional |
| Allocation: randomized intervention model. Double blind (caregiver, outcomes assessor) |
| Primary purpose: early diagnosis |
| Date of first enrolment | April 2021 |
| Target sample size | 150 |
| Recruitment status | Recruiting |
abnormalities. All meals will be monitored by pulse-oximetry and video recorded.

Lung ultrasound exam will be performed based on a previously described scanning scheme in children [25], as indicated in Fig. 2. Commercially available portable machines with a linear probe (9–12 MHz) with specific setting for infants will be used (Lumify, Philips Medical Systems, Andover, MA, USA). Acquired images and movies will be saved in both groups but only available for final analyses in the SC-m group. In detail, the thorax will be divided into 3 major scanning areas (anterior, lateral, and posterior) divided by the parasternal, anterior axillary, and posterior axillary anatomical lines on both the right and the left hemithorax. A deaeration score will be used to classify each LUS exams, taking into account the following signs in each scanning area: the number of B-lines; the appearance of the pleural line; presence of C-lines; presence of small peripheral sub-pleural consolidations; presence of large consolidations; presence of pleural effusion. A deaeration score will be calculated before and after the meal, so when the after-meal score will be different from pre-meal score (more than 10%), an intervention will be assigned to modify feeding performance and reported as medical, postural or food consistencies adaptation in the experimental group.

Assessments
Infants will be assessed for outcomes according to the timeline. At T0, neurological information will be collected by using the Hammersmith Infant Neurological Examination (HINE) [26]; Alberta Infant Motor Scale (AIMS, [27]), GMFCS E&R [28]. The clinical measures used are standardized and validated for use across a wide age range.

Clinical primary outcomes will be rate of pulmonary illness (including pneumonia, wheezing, chronic cough, and apnea rate) and performance at growth curves (according to WHO growth standards, eventually age-corrected because of premature birth, or according to specific syndrome growth standards as recommended by ESPGHAN [9]. Between T0 and T2, parents will be asked to fill a detailed respiratory infection-diary for respiratory illness rate calculation (information collected at both T1 and T2). We will consider the exact, separate number of upper and lower airways infection and detect patients suffering from RRI (Recurrent Respiratory Infections), according to the most recent definition, i.e. i) 6 or more airways infection/year (at least 1 pneumonia, even severe), or ii) 2 pneumonias even not severe but radiologically confirmed [29].

Primary outcome measure will include LUS score at T1. We assume that a better baseline detection of aspiration will result in better management with a reduction of pulmonary abnormalities detected by LUS at primary endpoint. Secondary outcomes collected at T1 will include chronic pain assessment (parents-report measures, behavioral measures including the Non-communicating Children’s Pain Checklist, and physiological measures) [30] and parents’ stress by a parent stress questionnaire (Parenting Stress Index PSI) [31]. At T0 and T2 laboratory exams will be performed to evaluate general and nutritional status (blood cells count, reticulocytes count, ferritin, total serum protein electrophoresis, prealbumin, transferrin, TSH, FT3, FT4, sodium, potassium, calcium, phosphorus, folates, vitamin B12, 25-OH-vitamin...
D, C-reactive protein, erythrocyte sedimentation rate, Insulin-like Growth Factor I) and quantitative ultrasound (QUS) also, in order to quantify bone mineralization.

VFSS and FEES data will be collected when performed according to multidisciplinary clinical indications, compared in frequency of execution between groups, and their results will be compared to LUS findings.

**Statistical analysis**

Statistical analyses will be performed by using a statistical software (Statistical Package for Social Sciences, SPSS). Descriptive statistics and baseline between group differences will be explored. Statistical significance will be considered at \( p < 0.05 \). Post-hoc adjustment will be applied for multiple comparisons. Changes in LUS-score, growth and pulmonary illness rates at the primary endpoint (T1) will be calculated to assess the short-term effects of LUS-management versus standard care. Secondary outcome measures will be calculated at T1 and T2. Covariates such as type of neurological impairment, type/severity of brain lesion and age, will be included in the analyses. Multivariate statistics will be finally performed. Data imputation will be considered according to characteristics and relationship of missing variables.

**Ethics**

The Paediatric Ethics Section of Tuscany Regional Ethics Committee on clinical trials (Italy) approved the presented study (study opinion registration number: 107/2019). Written consent will be obtained from parents of eligible infants, after being adequately informed about the trial by the Principal Investigator or the collaborators that have signed the ethical committee protocol. Relevant protocol modifications will be promptly communicated to the abovementioned Ethical Committee for approval revision.

According to recent recommendations on sensitive data management and patients’ privacy [32], an appropriate electronic password-protected access system for the correct de-identification/anonymization, collection, management, of patients’ data will be used. Participants’ identifying information will be stored separately with limited access.

**Discussion**

We describe the rationale and protocol for a RCT that evaluate the effectiveness of LUS-monitoring for meal-related pulmonary abnormalities due to silent or apparent aspiration events and the advantages of its clinical use in the management of pulmonary-related consequences of dysphagia, due to silent or apparent aspiration, in infants with neurological impairment. Aspiration is indeed common in children with neurological impairment, leading to acute and chronic lung disease, malnutrition, further neurodevelopmental disturbances, chronic pain and stressful interactions with caregivers. No guidelines are available for monitoring and management, in particular for younger ages (up to 3 years), when x-Ray VFSS or FEES have prudent application. LUS may support diagnosis and management, reducing times, avoiding expensive and unsafe repetition of X-Ray examinations in a vulnerable population. LUS may advice short-term and long-term risk for apparent and silent aspiration, resulting in a tailored and patient-centered management. This repeatable, cost-effective, safe LUS-monitored feeding procedure might represent a reliable and promising measure to monitor postural, habilitative, pharmacological treatment effectiveness and to improve the effectiveness of the multidimensional assessment and treatment of chronic discomfort in such a population.

In sum, we expect LUS to allow earlier, faster, more complete monitoring and diagnosis in order to systematically prevent complications, but also contributing to a deeper knowledge of physiopathological mechanisms underlying pulmonary diseases in this vulnerable population and establish risk category for prognosis. LUS may optimize and rationalize resources, by reducing expensive and dangerous x-Ray examinations or more invasive techniques. These results might be also translated to low-resources countries and settings.

**Abbreviations**

GERD: Gastroesophageal reflex; LUS: Lung Ultrasound; VFSS: Videofluoroscopic swallowing study; FEES: Fibre-opticendoscopic examination of swallowing; ESPGHAN: European Society of Gastroenterology, Hepatology, and Nutrition; RCT: Randomized Controlled Trial; MRI: Magnetic Resonance Imaging.

**Acknowledgements**

This paper is in memory of Prof Paolo Ghirri, University of Pisa.

**Authors’ contributions**

SF is the principal investigator; EM, RTS and LG are co-investigators; SF, RTS, EM, LG contributed to study conception, design and paper drafting; TC, CA and AM contributed to study design; LF and AG substantially revised the protocol and paper. All authors approved the submitted version of the paper.

**Funding**

This study was funded by the Italian Ministry of Health (https://ricerca.cbim.it; Bando Ricerca Finalizzata 2018, project: GR-2018–12367809) and partially supported by grant-RC and the 5 X 1000 voluntary contributions, Italian Ministry of Health. Neither sponsor had any role in study design, in the collection, analysis and interpretation of data, in the writing of the protocol paper, and in the decision to submit this protocol for publication.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not yet publicly available as the recruitment is ongoing, but they can be available from the corresponding author on reasonable request. The Principal Investigators and the formal research collaborators will have access to the final trial dataset.
Declarations

Ethics approval and consent to participate
The study was approved by the Pediatric Section of the Ethical Committee of the Tuscany Region for Experimental Studies, registration number 107/2019. The consent form is provided in Italian, adapted to local Ethics Committee guidelines and approved by the Ethical Committee.Written informed consent will be obtained from parents.

Consent for publication
Not applicable.

Competing interests
Authors have no competing interests to declare.

Author details
1 Department of Developmental Neuroscience, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS) Fondazione Stella Maris, Pisa, Italy. 2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 3 Department of Neonatal Intensive Care Unit, S. Chiara Hospital, Pisa, Italy. 4 Institute of Clinical Physiology, National Research Council of Italy (CNR), Pisa, Italy.

Received: 23 February 2022 Accepted: 11 June 2022
Published online: 23 June 2022

References
1. Quitadamo P, Thapar N, Staiano A, et al. Gastrointestinal and nutritional problems in neurologically impaired children. Eur J Paediatr Neurol. 2016;20(6):810–5. https://doi.org/10.1016/j.ejpn.2016.05.019 (Epub 2016 Jun 11. PMID: 27397730. Review).
2. Srivastava R, Jackson WD, Barnhart DC. Dysphagia and gastroesophageal reflux disease: dilemmas in diagnosis and management in children with neurodevelopmental disorders. Pediatr Ann. 2010;39(4):225–31.
3. Kuperminc MN, Gottrand F, Samson-Fang L, et al. Nutritional management of children with cerebral palsy: a practical guide. Eur J Clin Nutr. 2013;67(Suppl 2):S21–3. https://doi.org/10.1038/ ejcn.2013.227.
4. Fitzgerald DA, Follett J, Van Asperen PP. Assessing and managing lung disease and sleep disorders breathing in children with cerebral palsy. Paediatr Respir Rev. 2009;10(1):18–24. https://doi.org/10.1016/j.prrv.2008.10.003 (Epub 2009 Jan 23).
5. Arvedson J, Rogers B, Buck G, et al. Silent aspiration prominent in children with dysphagia. Int J PediatrOtorhinolaryngol. 1994;28(2–3):173–81.
6. Blackmore AM, Bear N, Blair E, et al. Factors Associated with Respiratory Illness in Children and Young Adults with Cerebral Palsy. J Pediatr. 2016;168:151-7.e1. https://doi.org/10.1016/j.jpeds.2015.09.064 (Epub 2015 Oct 29).
7. Pillai Riddell RR, Stevens BJ, McKeever P, et al. Chronic pain in hospitalized infants: health professionals’ perspectives. J Pain. 2009;10(12):1217–25.
8. Penagini F, Mameli C, Fabiano V, et al. Dietary Intakes and Nutritional Issues in Neurologically Impaired Children. Nutrients. 2015;7(11):9400–15. https://doi.org/10.3390/nu7115469.
9. Romano C, van Wynckel M, Hulst J, et al. European Society for Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children With Neurological Impairment. J Pediatr Gastroenterol Nutr. 2017;65(2):242–64. https://doi.org/10.1097/MPG.0000000000001646 (PMID: 28737572).
10. Dipasquale V, Gottrand F, Sullivan PB, et al Top-tend tips for managing nutritional issues and gastrointestinal symptoms in children with neurological impairment. Ital J Pediatr. 2020;46:35. https://doi.org/10.1186/ s13052-020-0890-0 (PMCID: PMC7099819. Published online 2020 Mar 27).
11. Benfer KA, Weir KA, Boyd RN. Clinimetrics of measures of oropharyngeal dysphagia for preschool children with cerebral palsy and neurodevelopmental disabilities: a systematic review. Dev Med Child Neurol. 2012;54(9):784–95.
12. Engel-Hoek LV, Erasmus CE, Hulst KC, et al. Children with central and peripheral neurologic disorders have distinguishable patterns of dysphagia on videofluoroscopic swallow study. J Child Neurol. 2014;29:646–53.
13. Calvo I, Conway A, Henriques F, et al. Diagnostic accuracy of the clinical feeding evaluation in detecting aspiration in children: a systematic review. Dev Med Child Neurol. 2016;58(6):541–53.
14. Cichero J, Nicholson T,Dodrill P. Liquid barium is not representative of infant formula: characterization of rheological and material properties. Dysphagia. 2011;26(3):264–71.
15. Novak I, Morgan C, Adde L, et al. Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment. JAMA Pediatr. 2017;171(9):897–907.
16. Uhm KE, Yi SH, Chang HJ, Cheon HJ, et al. Videofluoroscopic swallow study findings in full-term and preterm infants with Dysphagia. Ann Rehabil Med. 2013;37(2):175–82.
17. Krasaelap A, Kovacic K, Goday PS. Nutrition Management in Pediatric Gastrointestinal Motility Disorders. Nutr Clin Pract. 2020;35(2):265–72. https://doi.org/10.1002/ncp.10319 (Epub 2019 Jul 18 PMID: 31321821).
18. Volpicelli G, Elbarbary M, Blavas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38(4):577–91.
19. Raimondi F, Migliaro F, Sodano A, et al. Can neonatal lung ultrasound monitor fluid clearance and predict the need of respiratory support? Crit Care. 2012;16(6):R220.
20. Raimondi F, Migliaro F, Sodano A, et al. Use of neonatal chest ultrasound to predict noninvasive ventilation failure. Pediatrics. 2014;134(4):e1089–94.
21. Gargani L, Volpicelli G. How i do it: lung ultrasound. Cardiovasc Ultrasound. 2014;12(12):25.
22. Balk DS, Lee C, Schafer J, et al. Lung ultrasound compared to chest X-ray for diagnosis of pediatric pneumonia: A meta-analysis. Pediatr Pulmonol. 2018;53(8):1139–48.
23. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289–96.
24. Saudt J Anaeth. The CONSORT statement. 2019;13(Suppl 1):527-30. https://doi.org/10.4013/aja.SJA_559.18.
25. Cantinotti M, Att Ali L, Scalese M, et al. Lung ultrasound reclassification of chest X-ray data after pediatric cardiac surgery. Paedia Anaesth. 2018;28(S6):421–7.
26. Romeo DM, Ricci D, Brogna C, et al. Use of the Hammersmith Infant Neurological Examination in infants with cerebral palsy: a critical review of the literature. Dev Med Child Neurol. 2016;58(3):240–5. https://doi.org/10.1111/dmcn.12876 (Epub 2015 Aug 25 PMID: 26306473).
27. Snyder P, Eason JW, Philipbert D, Rodgway A, McLaughney T. Concurrent validity and reliability of the Alberta Infant Motor Scale in infants at dual risk for motor delays. Phys Occup Ther Pediatr. 2008;28(3):267–82.
28. Palisano R, Rosenbaum P, Bartlett D, et al. CanChild Centre for Childhood Disability Research, McMaster University. 2007.
29. La prevenzione delle infezioni respiratorie recorrenti - Consensus intersciettaria IRR 2020.
30. O'Rourke D. The measurement of pain in infants, children, and adolescents: from policy to practice. PhysTher. 2004;84(6):560–70.
31. Abidin RR. Parenting Stress Index-Fourth Edition (PSI-4). Lutz: Psychological Assessment Resources; 2012.
32. Tucker K, Branson J, Dilleen M, et al. Protecting patient privacy when sharing patient-level data from clinical trials. BMC Med Res Methodol. 2016;16(Suppl 1):77.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.